OS Therapies, Inc. ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today reported financial results for the third quarter of ...

Adagio Medical Holdings, Inc. (Nasdaq: ADGM; the "Company" or "Adagio"), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, today announced, today provided ...

Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical ...

Mori Arkin's appointment as interim CEO as of January 1, 2025 approved by shareholdersPhase 3 clinical trial of SGT-610 for Gorlin Syndrome is ongoing with over 40 clinical sites activatedSGT-210 proo ...

Kebilidi is the first approved gene therapy that can be directly administered to the brain. Its OK secures a priority review ...

The recent FDA approval of Kebilidi, a groundbreaking gene therapy for AADC deficiency, is a significant milestone for the company. It is the first gene therapy directly administered to the brain and ...

Arcutis Biotherapeutics has returned an impressive +200% YTD, following the successful product launch of Zoryve. See why I rate ARQT stock as a Strong Buy.

Liquidia's collaboration on L606 boosts long-term growth potential. Find out why LQDA stock’s valuation and upcoming launches ...

A European regulatory committee now recommends approval of the Alzheimer’s treatment lecanemab a few months after rejecting the drug.

Mori Arkin's appointment as interim CEO as of January 1, 2025 approved by shareholdersPhase 3 clinical trial of SGT-610 for Gorlin Syndrome is ...

Notes payable, plus accrued interest, totaled approximately $6.9 million. The current portion of the notes payable plus ...